COVID-19: Longitudinal immunological and multi-omic profiling of haemodialysis patients

  • Funded by Department of Health and Social Care / National Institute for Health and Care Research (DHSC-NIHR), UK Research and Innovation (UKRI)
  • Total publications:5 publications

Grant number: MR/V027638/1

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2021
  • Known Financial Commitments (USD)

    $385,678.41
  • Funder

    Department of Health and Social Care / National Institute for Health and Care Research (DHSC-NIHR), UK Research and Innovation (UKRI)
  • Principle Investigator

    Pending
  • Research Location

    United Kingdom, Europe
  • Lead Research Institution

    Imperial College London
  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Prognostic factors for disease severity

  • Special Interest Tags

    Gender

  • Study Subject

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Other

  • Occupations of Interest

    Unspecified

Abstract

COVID-19, caused by infection with SARS-CoV-2 ('coronavirus'), is a global emergency. Although most people suffer only mild symptoms, some people get seriously ill and the disease is deadly in around 1%. Patients with kidney disease are at high risk of developing serious illness. We urgently need new treatments for COVID-19. In order to develop them, we need to understand why some people get so ill. In these people, we think that the virus causes the body's immune system to goes into 'overdrive' and this causes collateral damage to the body. It is likely that this damage is caused by cells, genes and proteins involved in the immune response to the virus. To understand which ones are causing the problem, we have taken blood samples from patients with kidney disease who are receiving dialysis treatment 3 times a week and who have been infected with COVID-19. This means that we can look at blood samples over time to understand which genes are being switched on and which proteins are changing, particularly in patients who develop the most severe form of the disease. This will help us decide which drugs might help patients and improve survival.

Publicationslinked via Europe PMC

Last Updated:39 minutes ago

View all publications at Europe PMC

Multi-omics identify falling LRRC15 as a COVID-19 severity marker and persistent pro-thrombotic signals in convalescence.

Immuno-proteomic profiling reveals aberrant immune cell regulation in the airways of individuals with ongoing post-COVID-19 respiratory disease.

Protease inhibitor plasma concentrations associate with COVID-19 infection.

Plasma Lectin Pathway Complement Proteins in Patients With COVID-19 and Renal Disease.

Longitudinal proteomic profiling of dialysis patients with COVID-19 reveals markers of severity and predictors of death.